Lemborexant + Placebo
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Delayed Sleep Phase Syndrome
Conditions
Delayed Sleep Phase Syndrome
Trial Timeline
Mar 13, 2023 → May 31, 2027
NCT ID
NCT06874855About Lemborexant + Placebo
Lemborexant + Placebo is a approved stage product being developed by Eisai for Delayed Sleep Phase Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06874855. Target conditions include Delayed Sleep Phase Syndrome.
What happened to similar drugs?
2 of 3 similar drugs in Delayed Sleep Phase Syndrome were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07384429 | Approved | Recruiting |
| NCT06874855 | Approved | Recruiting |
| NCT04549168 | Phase 3 | Completed |
| NCT02952820 | Phase 3 | Completed |
Competing Products
8 competing products in Delayed Sleep Phase Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 43 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 21 |
| Belatacept + Calcineurin Inhibitor | Bristol Myers Squibb | Phase 2 | 31 |
| ARGX-117 | Argenx | Phase 2 | 36 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 23 |
| Desflurane + Propofol | Baxter | Approved | 40 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 41 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 11 |